Literature DB >> 6152742

Major psychosis and dopamine: controversial features and some suggestions.

R Miller.   

Abstract

Three problems with the dopamine hypothesis of major psychosis are pointed out: the long time-course of neuroleptic therapy; the absence of tolerance to the antipsychotic effects of neuroleptic drugs, or of a supersensitivity psychosis on drug withdrawal; and the absence of potent psychotogenic properties in the direct dopamine agonists. A resolution of these paradoxes is suggested relying on a role for dopamine in learning processes at a relatively high (cognitive) functional level. The hypothesis proposed is also used to explain the origin of some of the more distinctive psychotic symptoms.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6152742     DOI: 10.1017/s0033291700019759

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  4 in total

1.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

2.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 3.  The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness.

Authors:  R Miller
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Striatal Dopamine and Reward Prediction Error Signaling in Unmedicated Schizophrenia Patients.

Authors:  Teresa Katthagen; Jakob Kaminski; Andreas Heinz; Ralph Buchert; Florian Schlagenhauf
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.